Kassaian Nazila, Feizi Awat, Aminorroaya Ashraf, Amini Masoud
Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Professor of Biostatistics. Isfahan Endocrine and Metabolism Research Center and Department of Biostatistics and Epidemiology, Isfahan University of Medical Sciences, Isfahan, Iran.
Diabetes Metab Syndr. 2019 Sep-Oct;13(5):2991-2996. doi: 10.1016/j.dsx.2018.07.016. Epub 2018 Jul 30.
Modulation of the gastrointestinal microbiome is suggested to contribute to the progression of metabolic syndrome associated diseases. This study was designed to assess the effects of probiotics and synbiotics on metabolic syndrome in individuals with prediabetes.
120 adults with prediabetes were enrolled in a double-blind, placebo-controlled randomized parallel-group clinical trial. Participants were randomized to a multi-species probiotic or inulin-based synbiotic or placebo. Blood samples and anthropometric measures were collected at baseline, 12 and 24 weeks after treatment. The primary outcome measures were the changes between groups in metabolic syndrome and its components' prevalence.
A significant trend for a reduction in the prevalence of hyperglycemia in probiotic and synbiotic groups (p = 0.01 and 0.005 respectively), and hypertension in probiotic group (p = 0.04) was found. The decreases in metabolic syndrome prevalence were significant after taking probiotic and synbiotic supplementation as compared with placebo (p = 0.02). Also, the prevalence of low HDL-cholesterol level was decreased during the study in the probiotic group compared with placebo (p = 0.02).
The potential benefits of using probiotic and synbiotic for metabolic syndrome management in prediabetes have been supported by the results in the current study which might provide an important strategy to combat metabolic syndrome-associated diseases.
胃肠道微生物群的调节被认为与代谢综合征相关疾病的进展有关。本研究旨在评估益生菌和合生元对糖尿病前期个体代谢综合征的影响。
120名糖尿病前期成年人参加了一项双盲、安慰剂对照的随机平行组临床试验。参与者被随机分为多物种益生菌组、基于菊粉的合生元组或安慰剂组。在治疗前、治疗后12周和24周采集血样和人体测量指标。主要结局指标是代谢综合征及其各组分患病率在组间的变化。
发现益生菌组和合生元组高血糖患病率有显著下降趋势（分别为p = 0.01和0.005），益生菌组高血压患病率有显著下降趋势（p = 0.04）。与安慰剂相比，服用益生菌和合生元补充剂后代谢综合征患病率显著下降（p = 0.02）。此外，与安慰剂相比，益生菌组在研究期间低高密度脂蛋白胆固醇水平的患病率有所下降（p = 0.02）。
本研究结果支持了使用益生菌和合生元管理糖尿病前期代谢综合征的潜在益处，这可能为对抗代谢综合征相关疾病提供重要策略。
